Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899779 | 0.94 | HRH3 (0.34) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL6258518 | 0.92 | CYP4F2 (0.39) | CYP4F2CYP4A11DGAT1TSHR | |
| SCHEMBL6258085 | 0.91 | DGAT1 (0.37) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL6256870 | 0.90 | CYP4F2 (0.42) | CYP4F2CYP4A11DGAT1TSHR | |
| SCHEMBL20375533 | 0.88 | CYP4F2 (0.43) | CYP4F2CYP4A11DGAT1TSHR | |
| SCHEMBL5527551 | 0.86 | CYP4F2 (0.46) | CYP4F2CYP4A11DGAT1TSHR | |
| SCHEMBL11438402 | 0.83 | CYP4F2 (0.39) | CYP4F2CYP4A11DGAT1TSHR | |
| SCHEMBL27661776 | 0.82 | — | — | |
| SCHEMBL22016456 | 0.81 | ACLY (0.46) | CYP4F2CYP4A11TSHR | |
| SCHEMBL12803851 | 0.80 | DGAT1 (0.38) | CYP4F2CYP4A11DGAT1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005068410-A1 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-09-30 | — | — | US | claimed |
| CN-1894195-A | Ether compounds and compositions for cholesterol control and related uses | ESPERION THERAPEUTICS INC (US) | 2007-01-10 | — | — | CN | disclosed |
| US-6713507-B2 | CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; ALZHEIMER'S DISEASE | ESPERION THERAPEUTICS, INC. | 2004-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | CYP4F2 561/4885CYP4A11 51/4885DGAT1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.